Skip to main content
OpenTrials
Completed

NCT Number: NCT04955080

REal-time Data Monitoring for Shared Adaptive, Multi-domain and Personalised Prediction and Decision Making for Long-term Pulmonary Care Ecosystems (RE-SAMPLE)

The main objective of this RE-SAMPLE cohort study is to identify from a real-world data (RWD) set that will be collected, a subset of data that can be potentially used as important predictors and parameters for disease progression of COPD and complex chronic conditions, and multi-morbid exacerbations. The secondary objective is to evaluate the feasibility of RWD collection from a patient's perspective.

Study design: This is a prospective observational cohort study to collect RWD in patients with COPD and complex chronic conditions, with a maximum of 38 months of follow-up. Measurements are performed and RWD are collected by using the Healthentia mobile phone application at baseline (e.g. patient characteristics), daily (e.g. symptom diary), during follow-up visits and at deterioration, and from hospital data (e.g. healthcare visits). The choice of parameters and measurement tools that will be collected during the cohort will be updated every three months during the first year of the cohort (via protocol amendments). These updates are based on citizen-design sessions and on new literature insights. Prognostic models will be developed including predictors derived from the RWD collection.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical diagnosis of COPD according to the GOLD criteria [5] (FEV1 < 80% of the predicted value and FEV1/FVC < 0.70);
  • Patients can be included both at stable state and during exacerbation/hospitalization;
  • At least one comorbidity:

diabetes mellitus (glucocorticoid-induced, or stable type 1 or 2), chronic heart failure (clinical diagnosis according to the ESC guidelines), ischaemic heart disease (history of myocardial infarction, angina pectoris), active symptoms of anxiety and/or depression (≥11 Hospital Anxiety and Depression Scale , and/or anxiety or depression symptoms being treated at the time of inclusion);

  • Under treatment at one of the pilot sites (MST, TUK, GEM);
  • >40 years of age;
  • Smoker or ex-smoker;
  • Able to understand, read and write the language spoken in the country of the pilot site.
  • Accessibility to internet;
  • Written informed consent from the subject prior to participation.

Furthermore, 25% of the patients should also have ≥ 2 exacerbations, defined as respiratory problems that required a course of oral corticosteroids / antibiotics in the two years preceding study entry; and/or ≥ 1 hospitalisation for respiratory problems in the two years preceding study entry; and/or modified MRC (mMRC) score of 3 or 4 (COPD patients with these scores have a higher chance of exacerbating).

Exclusion criteria

  • Serious other diseases with a low survival rate;
  • Presence of any other active lung disease (e.g., sarcoidosis);
  • Severe psychiatric illness, diagnosed by anamnesis;
  • Maintenance therapy with antibiotics
  • Patients with cognitive impairment (Mini Mental State Examination (MMSE) < 24)

Treatment and study plan

Primary outcomes

  1. Predictors for exacerbations of COPD and comorbidities

    Time frame: Through study completion, an average of 2.5 years.

    Prognostic performance of the validated predictive model for COPD and comorbid exacerbations and disease progression from RWD. The measures for progression will be survival, based on all-cause mortality, as well as morbidity. Morbidity is defined as time until first hospitalisation for an acute exacerbation of COPD and CCC, time until first moderate COPD exacerbation, time until first pneumonia, and total number of COPD and CCC exacerbations (extracted from daily symptom diaries) and pneumonia.

Secondary outcomes

  1. Feasibility of the RWD collection.

    Time frame: Through study completion, an average of 1 year.

    This relates to the usability of the application for data collection. The system usability scale will be used as a benchmarking tool that measures the level of usability.

  2. Feasibility of the RWD collection.

    Time frame: Through study completion, an average of 1 year

    Assessment of the user experience associated with the data collection. The User Experience Questionnaire will be used to assess the user experience and as a benchmark. Furthermore, patients will be given the opportunity to articulate also in their own words how they experience the RWD collection.

Sponsors and collaborators

Lead sponsor

Medisch Spectrum Twente

Other

Collaborators

  • Atos IT Solutions and Services Iberia
  • Deutsches Forschungszentrum fur Kunstliche Intelligenz GMBH
  • Federation Europeenne des Hopitaux et des Soinds de Sante
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
  • Innovation Sprint
  • Roessingh Research and Development
  • Tartu Ülikooli Kliinikum
  • University of Piraeus
  • University of Twente

Registry information

Acronym: RE-SAMPLE

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Jul 8, 2021
Registry last updated
Dec 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.